Which prescription ophthalmic drops are used to treat dry eye disease?

Prescription Eye Drops for Dry Eye Disease

For moderate to severe dry eye disease, the primary prescription options are cyclosporine 0.05% (Restasis) or lifitegrast 5% (Xiidra), both dosed twice daily, with perfluorohexyloctane (Miebo) as a newer alternative specifically for evaporative dry eye associated with meibomian gland dysfunction. 1

First-Line Prescription Anti-Inflammatory Agents

When over-the-counter artificial tears fail to control symptoms, prescription therapy should be initiated with one of two FDA-approved anti-inflammatory agents:

Cyclosporine 0.05% (Restasis)

• Cyclosporine prevents T-cell activation and inflammatory cytokine production while inhibiting mitochondrial pathways of apoptosis, demonstrating success rates of 74% in mild, 72% in moderate, and 67% in severe dry eye disease. 1
• Standard dosing is one drop in each eye twice daily, with FDA approval based on trials showing a statistically significant 10-mm increase in Schirmer test results at 6 months in 15% of treated patients versus 5% of vehicle-treated patients. 1
• After one full year of twice-daily therapy, the dose can be decreased to once daily in select patients without loss of beneficial effects. 1
• Ocular burning occurs in approximately 17% of patients but is generally well tolerated, with prolonged improvement lasting a median of 20 months after discontinuation following 23 months of treatment. 1
• A newer water-free cyclosporine 0.1% formulation (Vevye) uses perfluorobutylpentane to enhance ocular delivery and demonstrated superior improvement in corneal fluorescein staining compared to vehicle at day 29. 2

Lifitegrast 5% (Xiidra)

• Lifitegrast blocks the LFA-1/ICAM-1 interaction, preventing T-cell activation and improving both signs and symptoms of dry eye disease over 3 months. 1, 3
• FDA approval in 2016 was based on studies showing benefit in both corneal/conjunctival staining and patient-reported symptoms including eye dryness score and ocular discomfort. 3
• Lifitegrast can be used as an alternative to cyclosporine for patients refractory to artificial tears, with demonstrated superiority over carboxymethylcellulose 0.5% in Indian patients. 3
• The medication appears safe over 12 months of use, though long-term effects beyond this period remain unknown. 3

Perfluorohexyloctane (Miebo) for Evaporative Dry Eye

Mechanism and Indication

• Perfluorohexyloctane is a first-in-class semifluorinated alkane that forms a monolayer at the air-liquid interface of the tear film to directly inhibit tear evaporation, specifically targeting evaporative dry eye associated with meibomian gland dysfunction. 1, 4
• This represents the first and currently only prescription treatment approved in the USA directly addressing the pathophysiology of excessive tear evaporation. 4

Clinical Evidence

• In the phase III GOBI and MOJAVE trials, perfluorohexyloctane instilled four times daily over 8 weeks resulted in statistically significant and clinically meaningful improvements in both signs and symptoms compared to hypotonic saline. 4
• Clinical trials showed consistent improvements in both signs and symptoms as early as 2 weeks, with sustained efficacy over 12 months in the KALAHARI extension study. 1, 4
• In Chinese patients with dry eye associated with meibomian gland dysfunction, perfluorohexyloctane demonstrated superior improvements in corneal fluorescein staining (mean difference -1.14) and eye dryness scores (mean difference -12.74) compared to saline at day 57. 5

Adjunctive Short-Term Corticosteroid Therapy

• Short-term topical corticosteroids (2-4 weeks maximum) can rapidly decrease ocular irritation symptoms and corneal fluorescein staining, but duration must be strictly limited to avoid complications including infection, intraocular pressure rise, and cataract formation. 1

Varenicline Nasal Spray (Tyrvaya)

• Varenicline is a highly selective nicotinic acetylcholine receptor agonist administered as a nasal spray that activates receptors on the trigeminal nerve within the nasal mucosa, stimulating the lacrimal functional unit to produce natural tears. 1
• This neuroactivator demonstrated clinically meaningful improvements in signs and symptoms of dry eye in randomized phase-3 trials and can be considered for patients with inadequate response to or intolerance of traditional eye drops. 1
• Unlike ophthalmic products that cause ocular discomfort upon instillation, varenicline does not cause ocular discomfort but can cause sneezing, cough, and throat/nose irritation in some patients. 6

Treatment Algorithm Based on Disease Severity

Moderate Dry Eye (Step 2)

• Initiate cyclosporine 0.05% or lifitegrast 5% twice daily when symptoms persist despite over-the-counter lubricants. 1
• Consider adding a short course (2-4 weeks) of topical corticosteroids for rapid symptom relief while initiating long-term anti-inflammatory therapy. 1

Severe Dry Eye with Evaporative Component

• Consider perfluorohexyloctane four times daily specifically for patients with meibomian gland dysfunction and excessive tear evaporation. 1, 4
• Concurrent treatment of underlying meibomian gland dysfunction with warm compresses and lid massage is essential for optimal outcomes. 1, 3

Critical Pitfalls to Avoid

• Do not extend topical corticosteroid therapy beyond four weeks, as this can lead to serious complications including infection, elevated intraocular pressure, and cataract formation. 1
• Do not overlook underlying blepharitis or meibomian gland dysfunction, which coexists in the majority of dry eye patients and will perpetuate symptoms despite prescription therapy. 1, 3
• Failing to recognize when to advance therapy from artificial tears to anti-inflammatory agents in moderate to severe disease leads to inadequate treatment. 1
• All prescription ophthalmic drops cause ocular discomfort upon instillation, which should be discussed with patients to improve compliance. 6

Practical Considerations

• Concurrent treatment of contributing factors such as blepharitis or meibomian gland dysfunction is essential for optimal outcomes with any prescription therapy. 3
• The squeezability of multidose preservative-free bottles requires significantly more force (26.68 ± 8.32 N) than other bottle types, which should be considered in patients with limited hand or pinch strength. 7
• Lifitegrast bottles require more force to squeeze (17.38 ± 2.13 N) than cyclosporine 0.5% (9.16 ± 0.80 N) or cyclosporine 0.9% (5.68 ± 0.40 N), potentially affecting administration and compliance. 7